Fundraising FoxIntensity Therapeutics
NASDAQ: INTSShelton, US · Founded 2012 · Delaware corporation · 1 known investors
Find your way into Intensity Therapeutics
Sign up to see every warm intro you have to Intensity Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Intensity Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Intensity Therapeutics is a clinical-stage biotech developing intratumoral drug delivery technology that injects therapeutic agents directly into solid tumors to kill cancer cells and trigger a systemic immune response. It targets patients with metastatic cancer as well as presurgical patients seeking to avoid disease recurrence.
Founders & leadership
Intensity Therapeutics was founded in 2012 by Lewis H. Bender and Ian B. Walters, M.D..
Board
Investors · 1
How we know: VCapital's portfolio page · funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$5.9M disclosed across 3 of 7 rounds · 1900–2024
▶$3.6MraisedDec 2024 · 1 investors · BiotechnologyRule 506(b)
- Thomas I.H. DubinDirector
- Mark A. GoldbergDirector
- Joseph TalamoExecutive Officer
- Emer LeahyDirector
- Lewis H. BenderExecutive Officer, Director
- Daniel DonovanDirector
- Offering amount
- $3.6M
- Amount sold
- $3.6M
- Sales commissions
- $120K
- Finders' fees
- $100K
- Placement agents
- Brookline Capital Markets, a division of Arcadia Securities, LLC, A.G.P./Alliance Global Partners
- First sale
- Nov 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$500KraisedJun 2015 · 1 investors · PharmaceuticalsRule 506(b)
- Lewis H. BenderExecutive Officer, Director
- Ian B. Walters, M.D.Executive Officer
- Offering amount
- $5M
- Amount sold
- $500K
- First sale
- May 2015
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
▶$1.8MraisedDec 2014 · 20 investors · PharmaceuticalsRule 506(b)
- Robert CookeExecutive Officer
- Lewis H. BenderExecutive Officer, Director
- Ian B. Walters, M.D.Executive Officer
- Amount sold
- $1.8M
- Sales commissions
- $40K
- Placement agents
- Cato Capital, LLC
- First sale
- Jan 2013
- Incorporated
- Corporation, Delaware, 2012
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
In the news
Frequently asked questions
- What does Intensity Therapeutics do?
- Intensity Therapeutics is a clinical-stage biotech developing intratumoral drug delivery technology that injects therapeutic agents directly into solid tumors to kill cancer cells and trigger a systemic immune response. It targets patients with metastatic cancer as well as presurgical patients seeking to avoid disease recurrence.
- Who founded Intensity Therapeutics?
- Intensity Therapeutics was founded by Lewis H. Bender, Ian B. Walters, M.D. in 2012.
- Who are Intensity Therapeutics's investors?
- Intensity Therapeutics's investors include VCapital.
- How much funding has Intensity Therapeutics raised?
- Intensity Therapeutics has disclosed $5.9M raised across 3 of its 7 known rounds.
- Where is Intensity Therapeutics headquartered?
- Intensity Therapeutics is headquartered in Shelton, US.